Singapore, March 26, 2009: Gene Bridges GmbH, the recombineering company, announced that Daiichi Sankyo Co., Ltd. of Tokyo, Japan has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method“, is a valued method for generating targeting vectors or modifying E. coli chromosomes.

 

“Recombineering is becoming the technology of choice in DNA engineering and with the help of Daiichi Sankyo Co., Ltd., we expect to gain further acceptance of Red/ET in industry and academia worldwide.” Mr Gary Stevens, CEO of Gene Bridges GmbH.

 

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods: Independent of restriction sites, No size limits, No unwanted mutations and Rapid.

 

Red/ET Recombineering is one simple tool to modify plasmids, BACs, and even E.coli chromosomes. Gene Bridges is represented in Japan by the distribution partner Funakoshi.